Dare Bioscience, Inc. quarterly report, Q1 FY2023

Dare Bioscience, Inc. — Q1 2023 Form 10-Q

Reporting period: Three months ended March 31, 2023. Dare is a clinical-stage women’s health biopharmaceutical company with one FDA-approved product, XACIATO, licensed to Organon for commercialization. It reported no revenue in the quarter.

Financial results and liquidity

MetricQ1 2023Q1 2022
RevenueNoneNone
Research and development expense$5.0 million$5.8 million
General and administrative expense$3.3 million$2.6 million
Total operating expenses$8.4 million$8.4 million
Net loss$8.0 million$8.4 million
Operating cash flow$(16.1) million$(12.3) million
Cash and cash equivalents, quarter-end$19.8 million$39.3 million

Q1 2023 loss per share was $0.09, compared with $0.10 in Q1 2022. No meaningful operating margin is available because the company recorded no quarterly revenue. The filing reports no borrowings; reported liabilities include lease obligations. Current assets were $29.5 million and current liabilities $24.3 million, for working capital of approximately $5.2 million. Cash includes $15.8 million of unspent grant funding restricted primarily to DARE-LARC1 and DARE-LBT development.

Changes versus the prior-year quarter

  • Net loss narrowed by approximately $0.4 million, while operating expenses were essentially flat.
  • R&D expense declined $0.8 million, mainly from lower Ovaprene clinical, manufacturing and regulatory costs and lower Sildenafil Cream study costs, partly offset by higher spending on earlier-stage programs.
  • G&A expense rose $0.8 million, including commercial-readiness costs and a one-time business-email-compromise fraud loss of approximately $0.2 million, net of insurance proceeds.
  • Operating cash use increased by approximately $3.8 million. The company attributed significant cash outflows to lower accrued expenses and deferred grant funding, among other working-capital changes.
  • Cash fell $14.8 million during the quarter. Exercise of warrants provided $1.3 million; 1.35 million shares were issued.

Outlook, developments and risks

  • Going concern: Management stated that available cash is insufficient for at least the next 12 months from issuance of the financial statements and that substantial doubt exists about the company’s ability to continue as a going concern. It said additional capital would be needed by mid-2023 if programs proceed on planned timelines. Failure to raise funds could force delays, reductions or termination of programs, or cessation of operations.
  • Financing: A new ATM agreement permits up to $50 million of common-stock sales, with a 3% commission; no shares were sold under it in Q1. In April and May, the company sold 106,000 shares for approximately $109,000 gross. The company also received $1.3 million from warrant exercises during Q1.
  • XACIATO: The first U.S. commercial sale was expected in Q2 2023. If achieved, Dare expected a $2.5 million Organon milestone, while a $0.5 million payment to a licensor would become due. Potential future revenue includes tiered royalties and milestones, but the filing reported no royalties or collaboration revenue through March 31.
  • Pipeline: Ovaprene Phase 3 recruitment was targeted for mid-2023; topline data from the Sildenafil Cream Phase 2b study were targeted for Q2 2023; DARE-PDM1 topline data were anticipated in 2023. The company planned to advance DARE-HRT1 toward Phase 3, subject to regulatory and development work. These are forward-looking targets, not assured outcomes.
  • The company expected R&D and G&A expenses to increase in 2023. Clinical success, regulatory approval, commercialization, collaborator performance, grant availability and access to financing remain material uncertainties.
  • Other notable risks include dependence on third parties for development and supply, potential dilution from equity financing, and clinical, regulatory, market-acceptance and reimbursement risks. The filing disclosed no material pending legal proceedings and no material changes to previously reported risk factors.

Key facts for investors to verify

  • Whether Dare obtained enough additional capital to fund operations and planned development, and the terms and dilution associated with financing.
  • Whether XACIATO launched as expected, and whether Organon sales generate milestone or royalty payments.
  • Progress and actual results for Ovaprene, Sildenafil Cream and DARE-PDM1 relative to stated study timelines.
  • How much of reported cash is available for general operations versus restricted grant-funded programs, and the pace of cash burn.
  • Subsequent share issuance and outstanding share count; 86,284,827 common shares were reported outstanding as of May 10, 2023.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.